双介入法治疗肝癌的临床研究  

The Clinical Study on Double Interventional Therapy for the Hepatic Carcinoma

作　　者：张祥林[1] 王刚[1] 

机构地区：[1]辽宁医学院附属第一医院放射线科,辽宁锦州121001

出　　处：《辽宁医学院学报》2010年第4期293-294,305,共3页Journal of Liaoning Medical University (LNMU) Bimonthly

摘　　要：目的研究与探讨肝动脉及门静脉双介入化疗栓塞对治疗原发性中晚期肝癌的临床疗效。方法 76例中晚期肝癌患者分为A、B两组,A组应用肝动脉与门静脉双介入灌注化疗及栓塞(TACE+SPVE)方法治疗患者35例,B组单纯采用肝动脉灌注化疗及栓塞(Transcatheter Arterial Chemoembolization,TACE)方法治疗患者41例。结果 A、B两组的有效率分别为85.7%和63.4%,治疗后6个月、12个月、18个月的生存率,A组为91.4%、82.8%、68.6%,B组为82.9%、61.0%、43.9%,两组12个月和18个月间差异有显著性意义(P<0.05)。结论应用肝动脉与门静脉双介入治疗中晚期肝癌,优于单纯肝动脉介入治疗的效果。Objective To investigate the clinical effectiveness of chemotherapy and embolization with double interventional therapy through hepatic artery and portal vein in middle or advanced stage of hepatic carcinoma. Methods 76 patients of middle or advanced stage of hepatic carcinoma were divided into two groups at random. There were 35 patients with chemotherapy and embolization of double intervcntional therapy through hepatic artery and portal vein in Group A and 41 patients with chemotherapy and embolizatian of interventional therapy through hepatic artery only in Group B. Results The effective rate was 85.7% and 63.4% in group A and group B respectively. The survival rate after therapy in six months, twelve months and eighteen months were 91.4% , 82. 8% and 68.6% in group A respectively, and 82.9%, 61.0% and 43.9% in group B, there were significant difference between the two groups in twelve and eighteen months （ P〈0. 05 ）. Conclusions The therapeutic effect of double interventional therapy through liver arterial and portal vein on middle or advanced stage of hepatic carcinoma is better than that of interventional therapy through hepatic artery.

关 键 词：肝癌 肝动脉 门静脉 双介入治疗 

分 类 号：R445[医药卫生—影像医学与核医学]